The abstract is read at the publisher; the summary is JClub's.
Intravesical Fc-optimized CD40 agonist 2141-V11 shows preliminary antitumor activity in 25 BCG-unresponsive NMIBC patients, with 40% responding and a 20-month median duration.
- Why it matters: CD40 agonists can stimulate dendritic cells and T-cell immunity, but systemic toxicity and limited biomarkers have constrained development and patient selection.
- What they did: In this phase I trial (NCT05126472), patients received weekly intravesical instillations for 3 weeks with retreatment at weeks 13 and 25; spatial multiplex profiling assessed immune correlates of response.
- The result: Responders had tertiary lymphoid structures with DC-CXCL13+ CD4+ and CD8+ T-cell triads, and post-treatment DC–Treg proximity decreased versus increased in non-responders.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.